期刊
NEUROIMAGE-CLINICAL
卷 2, 期 -, 页码 620-629出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2013.04.015
关键词
Alzheimer's disease; Neuroimaging; Promethazine; Amyloid plaques; MALDI-IMS
类别
资金
- VICC Cancer Center [R01CA160700, 5R01GM058008-14, P50CA128323]
- NATIONAL CANCER INSTITUTE [R01CA160700, P50CA128323] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB014841] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347, R01GM058008] Funding Source: NIH RePORTER
The identification of amyloid-binding compounds is a crucial step in the development of imaging probes and therapeutics for the detection and cure of Alzheimer's disease. Unfortunately, the process typically lags during the translation from in vitro to in vivo studies due to the impenetrable nature of the blood brain barrier (BBB). Here, we integrate fluorescence assay with MALDI imaging mass spectrometry to screen known compounds and repurpose their properties to enable the second function of binding to amyloid plaques. Through this approach, we identified an antihistamine compound, promethazine, that can bind to amyloid plaques. Finally, we demonstrate that promethazine is retained in the amyloid-burdened brain compared to a normal brain and that its distribution within the brain corroborates with that of amyloid plaques. (C) 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据